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Recent data have begun to elucidate the genetic architecture of schizophrenia, as well as provide new insights into
the relationships of specific genetic factors across diagnostic boundaries, with specific symptom domains, and in
the prediction of antipsychotic treatment response. Not
surprisingly, work conducted at the Maryland Psychiatric
Research Center (MPRC), led by Dr William Carpenter,
has helped to guide the thinking behind much of this work,
as well as contributed valuable data toward these efforts. In
this article, I will briefly summarize some of the major findings emerging from these lines of research and highlight the
role of the Dr Carpenter and his colleagues at the MPRC
in this area.
Key words: antipsychotic/pharmacogenetics/
polymorphism/psychosis
Molecular Genetic Overlap Across Psychiatric
Disorders
Although the development of DSM-III and its successors
greatly enhanced the reliability of psychiatric nosology, it
has become increasingly clear that its clinical syndromes
do not cleanly “carve nature at the joints.” For example,
overlap between schizophrenia and bipolar disorder has
been documented at multiple levels; including neuroanatomic and neurofunctional abnormalities,1 as well as clinical characteristics (ie, presence of psychotic features and
response to second-generation antipsychotics).2 At the
same time, other patients with psychosis are not adequately
captured by either category, receiving nonspecific diagnoses.3 These limitations in the current nosology may be
impeding attempts to understand the pathophysiology of
psychotic illness and develop clinically useful biomarkers.
Recently, large-scale genome-wide association studies (GWAS) have provided new data on the overlap
across psychiatric disorders. In 2009, the International

Schizophrenia Consortium4 published results from a
GWAS of 3322 subjects with schizophrenia and 3587
controls, in which, although only a limited number of
loci achieved genome-wide significance, the authors
were able to detect evidence for a polygenic component
to illness through use of a novel score test. Essentially,
as increasingly liberal thresholds of significance (as high
as P < .50) were utilized to identify potential risk alleles
in a arbitrarily selected discovery data set, these putative
risk alleles were able to differentiate schizophrenia cases
from controls in additional target data sets, including
independently collected data sets derived from different
ethnic groups. Most notably, however, these alleles also
explained significant, albeit modest, amounts of the variance in risk for bipolar disorder in 2 independent data
sets, with no significant evidence observed for overlap
with multiple nonpsychiatric disorders including diabetes and rheumatoid arthritis. These data suggesting polygenic overlap are supported by candidate gene studies
implicating a bipolar disorder risk gene, CACNA1C, in
risk for schizophrenia,5 as well as a recent study from the
Psychiatric Genomics Consortium (PGC) of over 60 000
subjects identifying shared loci across 5 disorders (autism
spectrum disorders, attention deficit hyperactivity disorder, major depressive disorder, bipolar disorder, and
schizophrenia), including CACNA1C.6 Taken together,
these recent studies provide considerable evidence that a
proportion of alleles that increase risk for schizophrenia
are not specific to schizophrenia but also impart risk for
other psychiatric disorders, including bipolar disorder.
Interestingly, Carpenter and colleagues’ early work
in the area of symptomatic overlap between psychiatric
disorders anticipates these molecular genetic results. In
the study by Carpenter et al,7 the authors investigated
the incidence of Schneider’s first rank symptoms (hallucinations, delusions, thought disorder etc.) commonly
believed to be pathognomic for schizophrenia, in a
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cohort of 131 psychiatrically ill subjects, including bipolar disorder patients, systematically characterized with a
structured interview with established reliability. Results
indicated that although first rank symptoms were present in the majority of the patients diagnosed with schizophrenia, that there was still a substantial proportion of
schizophrenia subjects who did not exhibit these symptoms, and that even among patients carefully diagnosed
with nonschizophrenia diagnoses, there was a substantial
incidence (23%) of these key symptoms. Carpenter stated
“we conclude that the postulated pathogenomonicity of
first rank symptoms is refuted,” solidly supporting the
hypothesis that symptomatic overlap could be observed
across disorders.
Genetics of Symptom Domains: The Importance of
Negative Symptoms
Data suggesting the overlap of symptoms across diagnostic groups have suggested an alternative to diagnosisbased genetic studies. For many years, the MPRC group
has been at the forefront of clinical and neurobiological investigations of a particularly important symptom
domain of illness, the negative symptoms. The negative
symptoms include blunted affect, avolition, and alogia
and have been shown to be enduring trait-like characteristics, relatively resistant to pharmacotherapy, and
linked to brain structural abnormalities. Carpenter and
colleagues developed the concept that these symptoms
can be primary, compared to secondarily associated with
medication or mood state, and introduced assessment
scales that could reliably rate these symptoms in a wide
range of patient populations8,9.
The criticality of negative symptoms is underscored by
the wealth of data linked negative symptom severity to
illness outcome. Palmer et al10 assessed functional status
in 83 patients with schizophrenia and found that more
severe negative symptoms were associated with poorer
outcome in terms of work history, independent living
status, and driving status. Bowie et al11 measured realworld outcome in 78 patients with schizophrenia using
the Specific Level of Function Scale and reported a significant influence of negative symptoms on interpersonal
skills but no significant effect on community activities or
work skills. These data in chronic subjects are consistent
with studies of first-episode and prodromal individuals.
Milev and colleagues12 evaluated 99 first-episode patients
and reported an association between negative symptoms
at intake and global psychosocial function at 7 years.
Both work function and impairment in relationships
were specifically predicted by baseline negative symptom
severity. Analyses of data collected at the Zucker Hillside
Hospital (ZHH) are consistent with this; in a longitudinal study of 250 patients with schizophrenia enrolled
within 6 months after hospital discharge and followed
for 18 months,13 we found that general cognitive ability
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and negative symptomatology are significant correlates
of overall disability. Zero-order correlations for each of
these 2 predictors with global functioning were −.33 and
.35, respectively (Ps < .001) (figure 1). By contrast, severity of positive and depressive symptoms was not significantly correlated with functional disability. Similarly, in a
separate cohort of 185 stable subjects with schizophrenia,
we demonstrated that negative symptoms specifically predicted work and social functioning.14
Notably, negative symptoms may be influenced by
genetic factors. Ross et al15 found that there was a significant sibling correlation for primary negative symptoms,
indicating a familial and therefore a potential genetic
contribution. To date, the majority of genetic studies
of negative symptoms have been candidate gene based,
predicated on the idea that genes implicated in risk for
schizophrenia may have more pronounced effects on specific symptom domains. For example, the gene DTNBP1
or dysbindin codes for a 40–50 kDa protein that binds
to β-dystrobrevin, a component of the dystrophin glycoprotein complex in the brain, and has been linked to
schizophrenia in several genetic studies.16–24 Notably,
studies suggest that DTNBP1 genotype may also influence the severity of negative symptoms in schizophrenia.
Fanous et al25 examined 755 subjects in the Irish Study
of High Density Schizophrenia and reported that a
DTNBP1 schizophrenia risk haplotype was significantly
overtransmitted to subjects with greater negative symptom ratings. Factors for hallucinations, delusions, and
depressive and manic symptoms were not related to the
high-risk DTNBP1 haplotype, and no other haplotype
within the sample was associated with negative symptoms. This relationship was not observed in a separate
study in an Irish case-control sample26; however, the
symptom factor structure differed between the 2 Irish
samples.
We also assessed the role of DTNBP1 variation in
schizophrenia and reported that 3 individual single nucleotide polymorphisms and a single 6-locus haplotype were
associated with schizophrenia and schizoaffective disorder in Caucasian subjects, albeit with a modest odds ratio.
Moreover, we observed that our DTNBP1 risk haplotype
was also associated with significantly (P = . 001) greater
negative symptoms in schizophrenia subjects.27 Risk haplotype carriers displayed significantly higher ratings than
noncarriers on each of the three 3 SCID-IV negative
symptom items: avolition (P = .039), alogia (P = .014),
and flattened affect (P = .016) (figure 2). The relationship was independent of an effect of the risk haplotype
on neurocognition,28 as a global neurocognitive measure
and WRAT-3 performance were included as covariates in
these analyses. These data provide evidence that DTNBP1
risk haplotypes may be associated with a greater degree
of negative symptoms in schizophrenia.
In addition to DTNBP1, other schizophrenia risk
variants, including a variant near the microRNA 137
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Fig. 1. Prediction of community function in the study of
schizophrenia.

Fig. 2. DTNBP1 Risk carriers: Negative Sx’s.

gene,29 have been implicated in negative symptom severity. Moreover, larger scale efforts are now underway to
assess the contribution of specific genetic factors to key
symptom domains.30 The PGC is amassing data from
thousands of subjects with more refined symptomatic
assessments to conduct a comprehensive genome-wide
analysis of symptom domains including negative symptoms. Finally, relatively large-scale studies within academia and the Veterans Administration system31 are
focusing their efforts on the identification of genes that
influence functional disability and may further highlight
the important role of genes that influence negative symptom severity. In all of this work, the contributions of Dr
Carpenter and colleagues toward the identification and
characterization of this critical domain of psychopathology are notable and provide further evidence of his key
role in advancing our understanding of the genetics of
mental illness.
Pharmacogenetics of Schizophrenia
The advances in molecular genetics have also provided the
impetus for renewed attempts to identify antipsychotic

drug-response predictors or pharmacogenetics. Some
of the earliest work focused on the prototypic atypical
antipsychotic agent clozapine for several reasons. First,
a number of important studies32,33 including some conducted by the MPRC group34 highlighted the fact that clozapine, among all other antipsychotic agents, appeared
to offer superior antipsychotic efficacy on poorly responsive or treatment-resistant patients. Second, clozapine
has affinities in the nanomolar range for dopaminergic,
serotonergic, noradrenergic, muscarinic, and histaminic
receptors, suggesting a number of potential candidate
systems for investigation in pharmacogenetic studies of
clozapine’s enhanced efficacy.35 Finally, clozapine’s association with the potentially fatal side effect of agranulocytosis required that treated patients undergo regular
venipuncture for white blood cell counts, and therefore
access to peripheral blood samples from which to extract
DNA was improved.36
The first generation of clozapine pharmacogenetic
studies was conducted by just a few groups, including a
collaborative group that included NIMH, NIAAA, and
MPRC investigators,37,38 and were candidate gene studies
focused on loci in the dopamine and serotonin receptor
systems. Arranz and colleagues39 initially attracted interest in the serotonin 5-HT2A T102C polymorphism with a
report of a significant (P = .02) association between the
102C allele and failure to respond to clozapine in a cohort
of 149 patients with chronic schizophrenia who were retrospectively assessed with a Global Assessment Scale.
These data were not replicated in a series of clozapine
studies from independent laboratories37,40–42 as well as in a
study that included typical antipsychotic agents.43 5-HT2A
T102C could be considered a relatively weak candidate
polymorphism because it does not result in an amino acid
substitution at the protein level, and there is little evidence
that it produces significant functional effects on 5-HT2A
receptor function.44 A less common polymorphism within
the 5-HT2A gene, His452Tyr, not in significant linkage disequilibrium with T102C37 has also not consistently been
found to be associated with clozapine response.37,40
Another obvious candidate for pharmacogenetic studies of antipsychotic drug response is the D2 receptor gene
(DRD2). To date, all known antipsychotic drugs have
potent affinities for the D2 receptor,45,46 and functional
brain imaging studies have suggested that D2 receptor
binding by antipsychotic agents may be “necessary and
sufficient” for antipsychotic efficacy.47 Even more recently
developed drugs that have targeted non-D2 receptors
without at least some element of D2 blockade have unfortunately failed to treat schizophrenia effectively, despite
early promise.48 However, there are few common polymorphisms within the coding regions of DRD2,49 and thus,
fewer studies of DRD2 and antipsychotic drug response
have been conducted compared with the 5-HT system.
Some of the earliest studies of DRD2 polymorphisms,
specifically, the −141C Ins/Del and Taq1A variants,
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revealed promising associations with antipsychotic efficacy, including data from the MPRC group.50 Although
the subsequent literature has been marked by mixed results
and small sample sizes, a pharmacogenetic meta-analysis51
composed of 687 patients reported that the 141C Ins/Del
polymorphism significantly influences antipsychotic drug
response, whereas there was not a significant relationship
between clinical response and the Taq1A variant. It can
be argued that these data, providing evidence that the
strongest candidate gene for antipsychotic drug response
is linked with clinical outcomes, provide proof of principle for these types of pharmacogenetic studies, including
larger scale GWAS studies,52 and it is notable that, once
again, Dr Carpenter and his group were critically involved
at the outset of this line of research.
Pharmacogenetic studies of antipsychotic druginduced adverse events have also been also been a focus
of current research. Clozapine-induced agranulocytosis
is a rare, but potentially serious adverse effect that limits
clozapine’s clinical utilization despite its enhanced efficacy in treating refractory schizophrenia. A candidate
gene-based pharmacogenetic study found an association between an allele at the HLA-DQB1 locus with risk
of agranulocytosis in 2 independent clozapine-treated
cohorts.53 Effect sizes were extremely high (OR = 16.86);
nearly 90% of allele carriers developed agranulocytosis.
Unfortunately, the overall sensitivity of the marker was
only 21%, which indicates that a majority of individuals
who develop agranulocytosis are not carriers of the allele
and presumably have other genetic risk factors. Thus, a
more comprehensive risk profile would be necessary in
order to obviate the need for invasive monitoring.
Unlike agranulocytosis, weight gain is a much more
common adverse effect of antipsychotic medications.
Recently, our group has found a strong genetic signal in
predicting antipsychotic-induced weight gain.54 An initial GWAS of antipsychotic-induced weight gain identified a top signal on chromosome 18q21 in a pediatric
sample prescribed antipsychotic drugs for the first time.
Risk allele homozygotes gained twice as much weight as
other patients after 12 weeks of treatment, with consistent effects observed on key metabolic parameters. This
result was replicated in 3 other independent samples, with
strikingly similar effect sizes.
This locus is approximately 150 kb downstream from
MC4R, the melanocortin 4 receptor gene, which has
been previously found to be associated with obesity in
the general population. MC4R-expressing neurons in the
ventromedial hypothalamus are regulated by circulating levels of leptin via pathways in the arcuate nucleus.
These leptin-sensitive pathways are regulated by 5-HT2C
receptors, which have also implicated in weight gain
in pharmacogenetic studies.55 The consistency of the
HTR2C-MC4R findings increases the possibility that
pharmacogenetically mediated intervention strategies
may soon be feasible.
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Conclusions
Emerging data from psychiatric genetics research suggests
a better understanding of the contribution of genetic variation to susceptibility to multiple psychiatric disorders, to
clinical symptom severity, and to the interindividual variability in antipsychotic drug response. In each of these
domains, the contributions of Dr William Carpenter and
his colleagues at the MPRC have been instrumental, and
our field has been greatly enhanced by his leadership in
these, as well as many others, areas of scientific inquiry.
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